The January 2027 PDUFA date for z-rostudirsen is the near-term binary catalyst. Watch for any FDA advisory committee meeting announcement or briefing documents ahead of the decision. Also monitor Q1 2027 ACHIEVE topline data for z-basivarsen, which could support a BLA submission.
Drugs in focus
DYN drug pipeline →z-rostudirsen
▲ Bullish Named in this press release- Impact
- Phase
- Filed (BLA under FDA Priority Review); Phase 3 confirmatory trial (FORZETTO) ongoing
- Time to market
- Potential U.S. launch in Q1 2027 if approved — BLA is under FDA Priority Review with a PDUFA target action date of January 21, 2027 (accelerated approval based on dystrophin as a surrogate endpoint).
- Next catalyst
- PDUFA date · Jan 21, 2027 66d
What to watchThe January 21, 2027 PDUFA is the binary to trade: approval odds look favorable (Priority Review, positive Phase 1/2 data, dystrophin surrogate endpoint), but an Accelerated Approval tied to a surrogate plus an unfinished confirmatory trial (FORZETTO) leaves room for a surprise CRL. Watch for an FDA Advisory Committee date in Q4 2026, the Q3 2026 earnings call for any label/launch commentary, and note the heavy 10b5-1 insider selling and ~57% weighted short-volume ratio as overhangs into the decision.
How the stock moved after the report
NEUTRAL VIEWSTOCK BELOW ENTRY AT T+5- T+0 · Nov 5 $17.36entry
- T+1 · 11d ago +4.09%α +3.78% · $18.07
- T+5 · 5d ago −2.02%α −5.31% · $17.01
- T+7 · todayOpen
- T+20 · in 17d Pending
- T+60 · in 3mo Pending
Price Chart
How similar events traded
Executive Summary
Dyne Therapeutics reported Q3 2026 net loss of $193.6M ($1.06/share), wider than the $108.0M loss a year ago, driven by increased R&D and G&A spending ahead of potential z-rostudirsen launch. The key catalyst is the January 21, 2027 PDUFA date for z-rostudirsen in DMD and Q1 2027 topline data from the ACHIEVE registrational cohort for z-basivarsen in DM1. Cash of $1.134B is expected to fund operations into Q2 2028.
Key Financial Metrics
Key Facts
- Q3 2026 net loss $193.6M ($1.06/share) vs $108.0M ($0.76/share) in Q3 2025
- R&D expenses $161.7M, up from $97.2M YoY; G&A $35.3M, up from $16.7M YoY
- Cash, equivalents and marketable securities $1.134B as of Sep 30, 2026
- BLA for z-rostudirsen (DYNE-251) under FDA priority review; PDUFA date Jan 21, 2027
- Topline data from ACHIEVE registrational expansion cohort for z-basivarsen (DYNE-101) expected Q1 2027
- Potential U.S. launch of z-rostudirsen expected Q1 2027 if approved; z-basivarsen launch expected H1 2028
- Four preclinical DMD programs (exons 44, 45, 53, 55) advancing
Financial Impact
Net loss widened by $85.5M YoY; cash burn rate increased; no revenue reported
Risk Factors
- FDA may not approve z-rostudirsen by the PDUFA date or at all
- ACHIEVE registrational cohort data may not support accelerated approval for z-basivarsen
- Cash burn is accelerating; $1.134B may not be sufficient if launch is delayed or additional trials are needed
- Competing DMD and DM1 therapies from other developers could limit commercial potential
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3396308 |
Track record
54 reports on DYN
12 of 16 bullish or bearish reports moved the stock their way by T+20. Best: +46.36% at T+60 after the May 20, 2026 report. 15 of 16 went positive at some point.
Filters
- Nov 16, 2026today SC 13G Neutral 3/10 Entry $16.77 Now $16.70 −0.39% settles Dec 15
- Nov 13, 20263d ago 144 Neutral 2/10 Entry $17.16 Now $16.70 −2.68% settles Dec 15
- Nov 13, 20263d ago 144 Neutral 2/10 Entry $17.16 Now $16.70 −2.68% settles Dec 15
- Nov 5, 202611d ago 8-K Neutral 5/10 No price data
- Nov 5, 202611d ago Press Release Neutral 5/10 Viewing Entry $17.36 Now $16.70 −3.80% settles Dec 4
- Oct 29, 202618d ago Institutional Cluster Neutral 2/10 Entry $17.04 Now $16.70 −2.00% settles Nov 27
- Oct 22, 202625d ago Press Release Neutral 2/10 Entry $15.62 Now $16.70 +6.91% settles Nov 20
- Oct 12, 20265w ago Institutional Cluster Mixed 4/10 Entry $15.96 to $18.62 Now $16.70 +4.64% ▲ +16.67% +19.93% vs SPY
- Sep 29, 20266w ago Press Release Bullish 7/10 Entry $16.11 to $16.94 Now $16.70 +3.66% ▲ +5.15% +4.23% vs SPY
- Sep 8, 20269w ago Insider Cluster Neutral 3/10 Entry $19.19 to $15.97 Now $16.70 −12.98% ▼ −16.78% −18.72% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers